Press Release

Apexigen to present at upcoming Investor Conferences

San Carlos, CA – February 19, 2019 – Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences:

Citi’s 7th Annual Immuno-oncology Leadership Summit
New York, NY
Tuesday, February 19, 2019 at 3:30 pm ET 

SVB Leerink’s 8th Annual Global Healthcare Conference
New York, NY
Wednesday, February 27, 2019 at 2:10 pm ET 

Cowen’s 39th Annual Healthcare Conference
Boston, MA
Tuesday, March 12, 2019 at 4:00 pm ET 

William Blair’s IO Conference
New York, NY
Thursday, March 21, 2019 at 2:05 pm ET

About Apexigen

Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that could harness the patient’s immune system to combat and eradicate cancer. APX005M and Apexigen’s additional preclinical programs were discovered using APXiMAB™, Apexigen’s proprietary product discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product candidates discovered using APXiMAB™ are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com.

Apexigen Contact:

Mark Nevins
Vice President, Business Development
650-931-6236
mnevins@apexigen.com